- Home
- CVBF vs RYTM Comparison
CVBF vs RYTM Comparison
Compare CVBF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVBF | RYTM |
|---|---|---|
| Founded | 1974 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CVBF | RYTM |
|---|---|---|
| Price | $18.65 | $107.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $23.88 | ★ $128.31 |
| AVG Volume (30 Days) | ★ 1.5M | 965.1K |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 4.30% | N/A |
| EPS Growth | ★ 4.23 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $509,488,000.00 | $174,334,000.00 |
| Revenue This Year | N/A | $47.34 |
| Revenue Next Year | $17.36 | $55.95 |
| P/E Ratio | $12.57 | ★ N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $16.01 | $45.91 |
| 52 Week High | $21.74 | $122.20 |
Technical Indicators
Market Signals| Indicator | CVBF | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 47.27 |
| Support Level | $19.06 | $106.00 |
| Resistance Level | $19.71 | $114.19 |
| Average True Range (ATR) | 0.44 | 4.98 |
| MACD | -0.17 | -0.61 |
| Stochastic Oscillator | 2.59 | 7.16 |
Price Performance
Historical ComparisonAbout CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.